Allogene Therapeutics, Inc. Form 8-K Summary
Reporting date: December 18, 2019. The filing reports executive compensation actions under Item 5.02; it does not provide financial statements or operating-period results.
Business Context and Reporting Period
Allogene Therapeutics is a Delaware biotechnology company listed on Nasdaq under the symbol ALLO. The Compensation Committee and Board reviewed 2020 executive compensation and 2019 corporate performance for the Chief Executive Officer, Chief Financial Officer, and Chief Technical Officer.
Compensation and Other Key Metrics
- David Chang, M.D., Ph.D., Chief Executive Officer and President: 2020 annual base salary increased from $600,000 to $675,000.
- Dr. Chang’s 2020 target annual cash bonus increased from 55% to 60% of annual base salary.
- Eric Schmidt, Ph.D., Chief Financial Officer, and Alison Moore, Ph.D., Chief Technical Officer: 2020 annual base salaries increased from $425,000 to $440,000 each.
- The Board approved 2019 cash bonuses equal to 110% of target annual cash bonus opportunities, prorated for partial-year service where applicable.
- Approximate approved 2019 bonuses were $363,000 for Dr. Chang and $187,000 each for Dr. Schmidt and Dr. Moore.
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other corporate financial metrics.
Material Changes Versus the Prior Comparable Period
The material changes disclosed are increases in 2020 executive base salaries and, for the CEO, the target annual cash bonus percentage. The filing states that the 2019 bonuses reflected achievement of all corporate goals, including a stretch goal.
Outlook, Management Commentary, Risks, and Unusual Items
The compensation increases were described as recognition of executive achievements and a retention measure. The filing contains no business guidance, financial outlook, risk-factor update, contingencies, or unusual operating items.
Investor Verification Items
- Verify the final 2020 executive compensation disclosures in the company’s subsequent proxy statement or annual filing.
- Confirm whether the approximate 2019 bonus amounts were subsequently paid as approved and whether any amounts were prorated.
- Review subsequent filings for the effect of these compensation changes on selling, general and administrative expenses and cash usage.
- Check later filings for any additional compensation, equity awards, or amendments to executive employment arrangements.